Value and Role of Incentives in Life Sciences
Do not miss the opportunity to be part of this important event as it aims to provide space for discussion on the proposed changes in the European pharmaceutical legislation and their consequences for the EU markets of innovative medicines.
The conference is collaboratively organised by Czech AIFP, Swedish Lif, Spanish Farmaindustria, and Belgian pharma.be, held under the auspices of the Minister of Health of the Czech Republic, Mr Vlastimil Válek, and supported by EFPIA.
We are bringing together thought leaders negotiating the proposal for General Pharmaceutical Legislation, experts on intellectual property rights, innovators, patients, and healthcare professionals. The purpose is to exchange ideas, share knowledge, and explore a vision for future development in the availability of innovative treatments in Europe based on the proposed reform of the European legislative framework for medicines.
Conference Details
Welcome to register for in-person or online attendance
Venue: Permanent Representation of the Czech Republic to the European Union (15, rue Caroly, Brussels)
Format: Hybrid (in-person and online)
Confirmed Speakers
- Sandra Gallina, Director-General, DG SANTE, European Commission
- Edita Hrdá, Ambassador, Head of the Czech Permanent Representation of the EU
- Dolors Montserrat, Member of the European Parliament
- Radka Maxová, Member of the European Parliament
- Jakub Dvořáček, Deputy Minister of Health of the Czech Republic
- Nathalie Moll, Director General, EFPIA
- Claus Runge, Senior Vice President, Global Head of Market Access, Public Affairs & Sustainability, Bayer
- Juan Yermo, Director General, Farmaindustria
- Julian Isla, Chief Scientific Officer, European Dravet Syndrome Federation
- Charlotte Weyne, Senior Legal Counsel & European Policy Advisor, pharma.be
- Laetitia Szaller, General Counsel & VP Corporate Development, AM Pharm
- Elaine Cruikshank, Founding Partner, Acumen